Background:

Manidipine is a calcium channel blocker that is used clinically as an antihypertensive. Target: Calcium ChannelManidipine is a dihydropyridine calcium antagonist, which causes systemic vasodilation by inhibiting the voltage-dependent calcium inward currents in smooth muscle cells. Manidipine was well tolerated in clinical trials, with most adverse effects related to vasodilation [1]. Manidipine is a lipophilic, third-generation dihydropyridine calcium channel antagonist with a high degree of selectivity for the vasculature, thereby inducing marked peripheral vasodilation with negligible cardiodepression. manidipine represents a first-line treatment option for patients with essential mild-to-moderate hypertension [2]. Manidipine has neutral effects on glucose and lipid metabolism and is generally well tolerated. Manidipine thus represents a first-line option for lowering BP in patients with mild-to-moderate hypertension [3].

参考文献:
[1]. Cheer, S.M. and K. McClellan, Manidipine: a review of its use in hypertension. Drugs, 2001. 61(12): p. 1777-99.
[2]. McKeage, K. and L.J. Scott, Manidipine: a review of its use in the management of hypertension. Drugs, 2004. 64(17): p. 1923-40.
[3]. Roca-Cusachs, A. and F. Triposkiadis, Antihypertensive effect of manidipine. Drugs, 2005. 65 Suppl 2: p. 11-9.